Table 3.
Geometric mean titers, individual ratio titers and seroconversion rates for V. cholera serogroups, by age group (full analysis set).
| 1–4 y | 5–14 y | ≥ 15 y | |||||
|---|---|---|---|---|---|---|---|
| (N = 112) |
(N = 112) |
(N = 112) |
|||||
| M or n/M | Mean titer, ratio or % (95% CI) | M or n/M | Mean titer, ratio or % (95% CI) | M or n/M | Mean titer, ratio or % (95% CI) | ||
| O1 Inaba | |||||||
| GMT, 1/dil | |||||||
| D0 | 112 | 2.74 (2.03; 3.71) | 112 | 18.7 (11.9; 29.4) | 112 | 35.6 (23.2; 54.6) | |
| D14 | 112 | 193 (118; 316) | 112 | 1103 (805; 1513) | 112 | 894 (672; 1189) | |
| D28 | 112 | 202 (132; 310) | 112 | 922 (707; 1202) | 111 | 636 (502; 807) | |
| Individual ratio titers | |||||||
| D14/ D0 | 112 | 70.2 (45.9; 108) | 112 | 59.1 (38.6; 90.4) | 112 | 25.1 (16.6; 38.1) | |
| D28/ D0 | 112 | 73.8 (49.9; 109) | 112 | 49.4 (32.8; 74.3) | 111 | 17.4 (11.7; 25.6) | |
| Seroconversion (≥ 4-fold rise) | |||||||
| D14/D0 | 98/112 | 87.5 (79.9; 93.0) | 99/112 | 88.4 (81.0; 93.7) | 93/112 | 83.0 (74.8; 89.5) | |
| D28/D0 | 100/112 | 89.3 (82.0; 94.3) | 97/112 | 86.6 (78.9; 92.3) | 87/111 | 78.4 (69.6; 85.6) | |
| O1 Ogawa | |||||||
| GMT (1/dil) | |||||||
| D0 | 112 | 2.56 (1.90; 3.45) | 112 | 18.2 (11.6; 28.7) | 112 | 68.5 (44.3; 106) | |
| D14 | 112 | 183 (115; 292) | 112 | 856 (637;1151) | 112 | 975 (764; 1244) | |
| D28 | 112 | 247 (169; 360) | 112 | 766 (593; 989) | 111 | 748 (600; 932) | |
| Individual ratio titers | |||||||
| D14/ D0 | 112 | 71.5 (46.4; 110) | 112 | 47.0 (30.4; 72.6) | 112 | 14.2 (9.64; 21.0) | |
| D28/ D0 | 112 | 96.3 (66.3; 140) | 112 | 42.0 (27.6; 64.0) | 111 | 10.5 (7.24; 15.3) | |
| Seroconversion (≥ 4-fold rise) | |||||||
| D14/D0 | 96/112 | 85.7 (77.8; 91.6) | 96/112 | 85.7 (77.8; 91.6) | 87/112 | 77.7 (68.8; 85.0) | |
| D28/D0 | 103/112 | 92.0 (85.3; 96.3) | 99/112 | 88.4 (81.0; 93.7) | 76/111 | 68.5 (59.0; 77.0) | |
| O139 | |||||||
| GMT (1/dil) | |||||||
| D0 | 112 | 3.36 (2.42; 4.66) | 112 | 5.31 (3.64; 7.74) | 112 | 7.68 (5.19; 11.4) | |
| D14 | 112 | 64.2 (46.9; 87.9) | 112 | 68.5 (51.5; 91.0) | 112 | 39.0 (28.1; 54.2) | |
| D28 | 112 | 20.5 (14.1; 29.9) | 112 | 57.8 (44.1; 75.8) | 111 | 29.7 (20.8; 42.3) | |
| Individual ratio titers | |||||||
| D14/ D0 | 112 | 19.1 (12.7; 28.8) | 112 | 12.9 (8.74; 19.1) | 112 | 5.08 (3.54; 7.29) | |
| D28/ D0 | 112 | 6.11 (4.15; 9.01) | 112 | 10.9 (7.45; 15.9) | 111 | 3.80 (2.69; 5.38) | |
| Seroconversion (≥ 4-fold rise) | |||||||
| D14/D0 | 78/112 | 69.6 (60.2; 78.0) | 70/112 | 62.5 (52.9; 71.5) | 47/112 | 42.0 (32.7; 51.7) | |
| D28/D0 | 56/112 | 50.0 (40.4; 59.6) | 69/112 | 61.6 (51.9; 70.6) | 39/111 | 35.1 (26.3; 44.8) | |
CI: confidence interval. M: number of participants with available data. n: number of participants with ≥ 4-fold rise in titers at the specified timepoint.
Note that 112 participants had data available for assessment of the immunogenicity endpoints at each time point for 1–4 and 5–14 y age groups, and for D0 and D14 for the ≥ 15 y age group; 111 participants had available data for D28 assessments in the ≥ 15 y age group.